| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_69c91bbf0395db010b4806f50d808c4e |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02P20-55 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-06026
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-06069
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-06078
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-04 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-81
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K5-065
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K5-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K5-062
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-113 |
| filingDate |
1981-02-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_980b74ca1dfb0f238d0ea7e69b0d9b70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d708bc3542247e48bff79af2c40e02d9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b167a572245f3b5da445558dbb9eec54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_25f88e07dfa2c69dc983e9c80b7c1caf
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6f6c46ab4c887237d6add10a9bdc9c62 |
| publicationDate |
1985-05-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CH-649561-A5 |
| titleOfInvention |
Agmatine derivatives with anticoagulant effect and process for their preparation |
| abstract |
The agmatine derivatives of the general formula I inhibit the coagulation of blood. The symbols in the formula I have the meaning stated in Claim 1. These compounds are prepared by condensing corresponding 1,4-diaminobutane derivatives of the general formula II with L-proline which is protected on the amino group and with the subsequent amino acid or else with an L-proline-peptide, by eliminating the protective group Q which is present where appropriate on the 1,4-diaminobutane moiety in the resulting compound, and converting the unblocked amino group into the guanidino group, removing from the resulting protected dipeptidyl-agmatine the protective group on the terminal amino group and the protective group Y which is present where appropriate on the guanidino group, and isolating the free dipeptidyl-agmatine in the form of a salt. <IMAGE> |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0330629-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/FR-2656608-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0330629-A2 |
| priorityDate |
1979-06-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |